Felix Tonagel

Felix Tonagel

Auto-generated profile, based on publicly available information

Felix Tonagel

Centre for Ophthalmology, University Eye Hospital, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Brain Communications
Verified
Journal Article
Open access
PDF file
majida charifmajida charif
majida charif
NGNaïg Gueguen
Naïg Gueguen
MFMarc FERRE
Marc FERRE
ZEZouhair Elkarhat
Zouhair Elkarhat
SKSalim Khiati
Salim Khiati
GLGuy Lenaers
Guy Lenaers
Biallelic mutations in ACO2, encoding the mitochondrial aconitase 2, have been identified in individuals with neurodegenerative syndromes, including infantile cerebellar retinal degeneration and recessive optic neuropathies (locus OPA9). By screening European cohorts of individuals with genetically unsolved inherited optic neuropathies, we identified 61 cases harbouring variants in ACO2, among whom 50 carried dominant mutations, emphasizing for the first time the important contribution of ACO2 monoallelic pathogenic variants to dominant optic atrophy. Analysis of the ophthalmological and clinical data revealed that recessive cases are affected more severely than dominant cases, while not significantly earlier. In addition, 27% of the recessive cases and 11% of the dominant cases manifested with extraocular features in addition to optic atrophy. In silico analyses of ACO2 variants predicted their deleterious impacts on ACO2 biophysical properties. Skin derived fibroblasts from patients harbouring dominant and recessive ACO2 mutations revealed a reduction of ACO2 abundance and enzymatic activity, and the impairment of the mitochondrial respiration using citrate and pyruvate as substrates, while the addition of other Krebs cycle intermediates restored a normal respiration, suggesting a possible short-cut adaptation of the tricarboxylic citric acid cycle. Analysis of the mitochondrial genome abundance disclosed a significant reduction of the mitochondrial DNA amount in all ACO2 fibroblasts. Overall, our data position ACO2 as the third most frequently mutated gene in autosomal inherited optic neuropathies, after OPA1 and WFS1, and emphasize the crucial involvement of the first steps of the Krebs cycle in the maintenance and survival of retinal ganglion cells.

28 January 2022 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
SKSinja Kieninger
Sinja Kieninger
TXTing Xiao
Ting Xiao
NWNicole Weisschuh
Nicole Weisschuh
SKSusanne Kohl
Susanne Kohl
KRKlaus Rüther
Klaus Rüther
FTFelix Tonagel
Felix Tonagel
Background: Leber’s hereditary optic neuropathy (LHON) has been considered a prototypical mitochondriopathy and a textbook example for maternal inheritance linked to certain disease-causing variants in the mitochondrial genome. Recently, an autosomal recessive form of LHON (arLHON) has been described, caused by disease-causing variants in the nuclear encoded gene DNAJC30. Methods and results: In this study, we screened the DNAJC30 gene in a large Central European cohort of patients with a clinical diagnosis of LHON or other autosomal inherited optic atrophies (OA). We identified likely pathogenic variants in 35/1202 patients, corresponding to a detection rate of 2.9%. The previously described missense variant c.152A>G;p.(Tyr51Cys) accounts for 90% of disease-associated alleles in our cohort and we confirmed a strong founder effect. Furthermore, we identified two novel pathogenic variants in DNAJC30: the nonsense variant c.610G>T;p.(Glu204*) and the in-frame deletion c.230_232del;p.(His77del). Clinical investigation of the patients with arLHON revealed a younger age of onset, a more frequent bilateral onset and an increased clinically relevant recovery compared with LHON associated with disease-causing variants in the mitochondrial DNA. Conclusion: This study expands previous findings on arLHON and emphasises the importance of DNAJC30 in the genetic diagnostics of LHON and OA in European patients.

18 December 2020 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
FTFelix Tonagel
Felix Tonagel
HWHelmut Wilhelm
Helmut Wilhelm
PRPaul Richter
Paul Richter
CKCarina Kelbsch
Carina Kelbsch
Purpose: In September 2015, the first and so far only medication for treatment of Leber’s hereditary optic neuropathy (LHON) was approved in the EU. The drug in question is idebenone (©Raxone) and has been given to all newly diagnosed patients of the University Eye Hospital Tuebingen since the approval of the drug. The aim of the study was to find out whether regular administration of the drug led to an improvement in vision. We retrospectively examined 2 cohorts of consecutive patients with newly occurred visual impairment and LHON diagnosis: One with the initial diagnosis made from January 2010 until April 2014 and a second from October 2015 until January 2020. Methods: Retrospective, observational cohort study. All electronic medical files of newly diagnosed and genetically confirmed LHON patients of the University Eye Hospital Tuebingen from January 2010 until April 2014 (cohort 1) and October 2015 until January 2020 (cohort 2) with at least 12 months of follow-up examinations have been analyzed. Results: Five patients were included in the first and 7 patients in the second cohort. Patients of cohort 1 received no medication; patients of cohort 2, a daily dose of 900 mg idebenone. The primary visual acuity (VA) ranged between 0.03 and 0.5 in cohort 1 and did not improve during the observation period (median 60 months, range 23–87 months). The patients of cohort 2 have been observed for a median of 23 months (range 12–35 m). The primary VA ranged from 0.01 to 0.16. A recovery in one or both eyes with a final VA from 0.8 to 1.0 was experienced in 3 out of 7 patients. All patients showing a recovery of VA carried the m.11778G>A mutation. Conclusion: The observed improvement in the treated cohort may be considered as a hint on the efficacy of idebenone in LHON. The time course of improvement suggests that idebenone should be given 1.5 years in newly diagnosed LHON cases.

13 December 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
CKCarina Kelbsch
Carina Kelbsch
KSKrunoslav T. Stingl
Krunoslav T. Stingl
Ronja JungRonja Jung
Ronja Jung
MKMelanie Kempf
Melanie Kempf
PRPaul Richter
Paul Richter
FTFelix Tonagel
Felix Tonagel
Purpose: To examine systematically how prechiasmal, chiasmal, and postchiasmal lesions along the visual pathway affect the respective pupillary responses to specific local monochromatic stimuli. Methods: Chromatic pupil campimetry (CPC) was performed in three patient groups (10 subjects with status after anterior ischemic optic neuropathy, 6 with chiasmal lesions, and 12 with optic tract or occipital lobe lesions (tumor, ischemia)) using red, low-intensity red, and blue local stimuli within the central 30° visual field. Affected areas - as determined by visual field defects revealed using conventional static perimetry - were compared with non-affected areas. Outcome parameters were the relative maximal constriction amplitude (relMCA) and the latency to constriction onset of the pupillary responses. Results: A statistically significant relMCA reduction was observed in the affected areas of postchiasmal lesions with red (p = 0.004) and low-intensity red stimulation (p = 0.001). RelMCA reduction in the affected areas seemed more pronounced for low-intensity red stimulation (46.5% mean reduction compared to non-affected areas; 36% for red stimulation), however statistically not significant. In prechiasmal lesions, a statistically significant latency prolongation could be demonstrated in the affected areas with low-intensity red stimulation (p = 0.015). Conclusion: Our results indicate that the choice of stimulus characteristics is relevant in detecting defects in the pupillary pathway of impairment along the visual pathway, favoring red stimuli of low intensity over blue stimuli. Such knowledge opens the door for further fundamental research in pupillary pathways and is important for future clinical application of pupillography in neuro-ophthalmologic patients.

23 September 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
FTFelix Tonagel
Felix Tonagel
HWHelmut Wilhelm
Helmut Wilhelm
CKCarina Kelbsch
Carina Kelbsch
PRPaul Richter
Paul Richter
Background/objectives: The correct classification of a slowly progressing optic atrophy can be challenging. The aim of this work was to find out if the characteristics of peripapillary retinal nerve fiber layer (RNFL) thickness loss differ between open angle glaucoma (POAG), optic nerve sheath meningioma (ONSM), and sphenoid wing meningioma (SWM). Methods: A total of 45 patients with POAG, ONSM, and SWM were included in the retrospective study. The peripapillary RNFL thickness measured by spectral-domain optical coherence tomography was analyzed using the Heidelberg Engineering glaucoma module©. Results: Each group consisted of 15 patients. The temporal sector of the RNFL thickness showed a median decrease of − 17 µm in glaucoma patients (range + 6/–34 µm), − 43 µm in ONSM (range − 19/ − 52 µm), and − 44 µm in SWM patients (range − 25/ − 52 µm). The RNFL thickness of the temporal sector of glaucoma patients differed significantly from the other groups (p < 0.001). All other sectors showed no significant difference between the 3 groups. Conclusion: The peripapillary RNFL thickness of the temporal sector of patients with beginning to moderate POAG is usually inside normal limits or borderline. In contrast, patients with ONSM and SWM are much more likely to show a considerable reduction in RNFL thickness of the temporal sector. RNFL thickness of the temporal sector marked outside normal limits occurred exclusively in meningioma patients. Considering the presence of this condition as a predictor for meningioma, sensitivity and specificity were 0.8 and 1.0, respectively. In patients with significant reduction in RNFL thickness of the temporal sector, magnetic resonance imaging of the head should be considered to rule out compression of the optic nerves.

24 September 2013 in Klinische Monatsblätter für Augenheilkunde
Verified
Journal Article
Closed access
CKC. Kernstock
C. Kernstock
KFK. Friebe
K. Friebe
FTF. Tonagel
F. Tonagel
Die optische Kohärenztomografie (OCT) hat die Augenheilkunde revolutioniert. Auch bei neuroophthalmologischen Krankheitsbildern gibt es dank moderner, hochauflösender Geräte immer mehr Anwendungsfälle. In dieser Übersichtsarbeit werden die im OCT feststellbaren Veränderungen und deren Relevanz für den klinischen Alltag bei folgenden Krankheitsbildern besprochen: autosomal dominante Optikusatrophie (adOA), Lebersche hereditäre Optikusneuropathie (LHON), toxische, traumatische und kompressive Optikusatrophie, Drusenpapillen, anteriore ischämische Optikusneuropathie (AION), Grubenpapillen, Stauungspapillen, Neuritis nervi optici (NNO) (isoliert, im Rahmen einer Multiplen Sklerose oder Neuromyelitis optica), neurodegenerativen Erkrankungen und Netzhautdystrophien. Oftmals ist eine Diagnose allein aufgrund der Veränderungen im OCT nicht möglich, jedoch finden sich bei einigen Krankheitsbildern pathognomonische Befunde, die klar auf eine bestimmte Genese hindeuten. Gerade bei den oft komplexen Sachverhalten in der Neuroophtalmologie ist das OCT – mehr noch als sonst – jedoch immer als zusätzliche Modalität und nicht als Ersatz anderer Untersuchungen zu sehen. Optical coherence tomography (OCT) has revolutionised ophthalmology. Due to modern instruments with extremely high resolution there are more and more applications also in neuro-ophthalmological disorders. This review gives an overview on typical changes in OCT for the following diseases: autosomal dominant optic atrophy, Leber hereditary optic neuropathy, toxic, traumatic and compressive optic neuropathy, optic nerve drusen, anterior ischaemic optic neuropathy, optic disc pit, papilledema, optic neuritis (isolated or associated with multiple sclerosis or neuromyelitis optica), neurodegenerative diseases and hereditary retinal diseases. A diagnosis exclusively based on an OCT examination is not always possible, but in several diseases there are pathognomonic changes that directly lead to the correct diagnosis. Particularly with the often complex settings in neuro-ophtalmology the OCT should be seen as a supplementary modality and not as a replacement for other techniques.